Research shows that a protein called NAT10 in liver cells helps produce TGFβ1, a molecule that triggers immune cells to activate scar-forming cells in fatty liver disease. When researchers blocked NAT10 in mice, liver scarring decreased significantly. This discovery identifies a new potential drug target, though human treatments are still years away. Current proven approaches—weight loss, reducing sugar, and exercise—remain the best strategies for people with fatty liver disease.
According to Gram Research analysis, scientists discovered how fat-damaged liver cells send chemical signals that cause scarring in fatty liver disease. The study found that a protein called NAT10 helps liver cells produce a molecule called TGFβ1, which activates immune cells in the liver. These immune cells then trigger scar-forming cells to create fibrosis (scarring tissue). When researchers blocked NAT10 in mice, the liver produced less TGFβ1, fewer immune cells became activated, and liver scarring decreased. This discovery could lead to new treatments for fatty liver disease by targeting the communication between different liver cell types.
Key Statistics
A 2026 research study found that blocking NAT10 in liver cells reduced TGFβ1 production and decreased pro-fibrotic Kupffer cell activation in mice with high-fat diet-induced fatty liver disease.
In laboratory experiments, Kupffer cells exposed to conditioned media from NAT10-deficient hepatocytes showed significantly reduced activation of hepatic stellate cells compared to cells exposed to normal hepatocyte media.
Molecular analysis revealed that TGFβ1 messenger RNA showed reduced ac4C chemical modifications and lower stability when NAT10 was knocked down in lipotoxic hepatocytes, suggesting NAT10 directly controls TGFβ1 production.
In vivo studies demonstrated that hepatocyte-specific NAT10 knockdown in mice fed a high-fat, high-fructose diet resulted in decreased hepatic TGFβ1 levels and alleviated liver fibrosis compared to control mice.
The Quick Take
- What they studied: How liver cells communicate with immune cells and scar-forming cells in fatty liver disease, specifically looking at a protein called NAT10 and a signaling molecule called TGFβ1
- Who participated: Laboratory-grown liver cells (Hepa1-6 cells), primary mouse liver cells, immune cells called Kupffer cells, scar-forming cells called hepatic stellate cells, and mice fed a high-fat, high-fructose diet
- Key finding: Blocking NAT10 in liver cells reduced TGFβ1 production, which decreased immune cell activation and reduced liver scarring in mice with fatty liver disease
- What it means for you: This research identifies a new target (NAT10) that could potentially be blocked to reduce liver scarring in people with fatty liver disease. However, this is early-stage research in animals and cells, so human treatments are still years away. People with fatty liver disease should focus on proven approaches like weight loss, reducing sugar intake, and exercise while researchers develop new therapies.
The Research Details
This was a multi-part laboratory study combining cell culture experiments with animal testing. Researchers first used fat-exposed liver cells in dishes, removing or keeping the NAT10 protein to see how it affected TGFβ1 production. They then collected the liquid surrounding these cells (called conditioned media) and exposed immune cells and scar-forming cells to it, observing how they responded. Finally, they tested their findings in living mice by genetically reducing NAT10 specifically in liver cells using a viral delivery system, then fed these mice a high-fat, high-fructose diet to trigger fatty liver disease.
The researchers used several measurement techniques to track what was happening. They measured ac4C (a chemical modification on RNA molecules) using specialized tests, checked how long TGFβ1 messenger RNA survived in cells, and examined which genes were turned on or off. They also looked at liver tissue under microscopes to see if scarring had developed.
This approach allowed researchers to move from simple cell experiments to more complex systems (multiple cell types interacting) to living animals, building confidence that their findings reflect real biological processes.
Understanding how liver cells communicate with immune cells is crucial because fatty liver disease affects millions of people worldwide and can progress to serious scarring (cirrhosis). Most current treatments focus on weight loss and lifestyle changes, but they don’t work for everyone. By identifying the NAT10-TGFβ1 pathway, researchers have found a specific molecular target that could be blocked with drugs to slow or prevent scarring, even if someone can’t lose weight quickly enough.
This study has several strengths: it uses multiple experimental approaches (cell culture, animal models, molecular measurements), includes both laboratory-grown and primary cells (which behave more like real cells), and tests findings in living animals. The research was published in a peer-reviewed scientific journal. However, the study doesn’t specify exact sample sizes for all experiments, and animal studies don’t always translate to humans. The findings are preliminary and would need human clinical trials before becoming a treatment.
What the Results Show
When researchers removed NAT10 from fat-exposed liver cells, the cells produced significantly less TGFβ1, a signaling molecule that triggers inflammation and scarring. This reduction occurred without harming the liver cells themselves. When immune cells (Kupffer cells) were exposed to liquid from normal fat-exposed liver cells, they became activated and expressed genes associated with pro-fibrotic activity (Spp1 and Lgals3). However, when these immune cells were exposed to liquid from liver cells lacking NAT10, this activation was much weaker.
In a more complex system where Kupffer cells and scar-forming cells (HSCs) were grown together, Kupffer cells primed by normal hepatocyte-conditioned media dramatically increased HSC activation, shown by increased production of α-SMA and Collagen I (markers of scarring). When Kupffer cells were instead exposed to media from NAT10-deficient hepatocytes, HSC activation was significantly reduced. Adding back recombinant TGFβ1 partially restored this HSC activation, confirming that TGFβ1 is a key molecule in this communication chain.
Molecular analysis revealed that TGFβ1 messenger RNA had reduced ac4C modifications (a chemical tag on RNA) and lower stability when NAT10 was knocked down, suggesting that NAT10 directly controls how long TGFβ1 instructions persist in cells.
In living mice with hepatocyte-specific NAT10 knockdown fed a high-fat, high-fructose diet, liver TGFβ1 levels were reduced compared to control mice. The livers of NAT10-deficient mice showed fewer pro-fibrotic Kupffer cells (identified as CLEC4F+LGALS3+ cells), and histological examination revealed less liver fibrosis (scarring). These in vivo findings confirm that blocking NAT10 in liver cells has protective effects against scarring in the context of fatty liver disease.
This research builds on existing knowledge that TGFβ1 is a major driver of liver fibrosis and that communication between different liver cell types is critical for disease progression. Previous studies showed that Kupffer cells (liver immune cells) can activate HSCs (scar-forming cells), but the specific hepatocyte-derived signals controlling this interaction were not well understood. This study identifies NAT10-mediated ac4C modification as a previously unknown mechanism controlling TGFβ1 production, adding a new layer to our understanding of how fatty liver disease progresses to scarring.
The study was conducted primarily in mice and laboratory cell systems, which may not perfectly reflect human liver disease. The exact sample sizes for many experiments are not specified in the abstract. The research focuses on one specific pathway (NAT10-TGFβ1), but fatty liver disease involves many other molecular mechanisms that weren’t examined here. While recombinant TGFβ1 partially restored HSC activation, this doesn’t prove TGFβ1 is the only important factor. The study doesn’t examine whether NAT10 inhibition might have unwanted side effects in other tissues or organs. Finally, no human clinical trials have been conducted, so it’s unknown whether blocking NAT10 would be safe or effective in people.
The Bottom Line
This research is too preliminary for clinical recommendations. It identifies a potential drug target (NAT10) but doesn’t provide evidence that blocking it would be safe or effective in humans. Current evidence-based recommendations for fatty liver disease remain: maintain a healthy weight, reduce sugar and refined carbohydrate intake, exercise regularly, limit alcohol, and work with a healthcare provider to manage metabolic conditions like diabetes. People with fatty liver disease should continue following these proven approaches while researchers develop and test new therapies based on discoveries like this one.
This research is most relevant to: (1) people with fatty liver disease or metabolic syndrome who are interested in emerging treatments, (2) researchers studying liver disease and fibrosis, (3) pharmaceutical companies developing new drugs, and (4) hepatologists (liver specialists) staying current with mechanistic research. This should NOT be interpreted as a treatment recommendation for anyone currently. People without fatty liver disease don’t need to take action based on this research.
If NAT10 inhibitors are developed and tested in humans, it would likely take 5-10 years minimum before any new treatment becomes available. Early-stage drug development, safety testing, and clinical trials all require significant time. People shouldn’t expect this specific pathway to translate into a treatment in the near term.
Frequently Asked Questions
What is NAT10 and why does it matter for fatty liver disease?
NAT10 is a protein in liver cells that controls how long TGFβ1 messenger RNA survives. TGFβ1 triggers immune cells to activate scar-forming cells. Blocking NAT10 reduced scarring in mice with fatty liver disease, making it a potential drug target for future treatments.
How do liver cells communicate with immune cells to cause scarring?
Fat-stressed liver cells produce TGFβ1, which activates immune cells called Kupffer cells. These activated Kupffer cells then trigger scar-forming cells (HSCs) to produce collagen and create fibrosis. This study shows NAT10 controls this communication chain.
Can I use this research to treat my fatty liver disease right now?
No. This is early-stage research in mice and cells. No human treatments based on NAT10 inhibition exist yet. Proven approaches remain weight loss, reducing sugar intake, exercising regularly, and working with your doctor to manage metabolic conditions.
When will NAT10-blocking drugs be available for people?
If drug development proceeds successfully, it would likely take 5-10 years minimum before any NAT10 inhibitor becomes available for human use. This requires drug development, safety testing, and clinical trials—all lengthy processes.
Does this research mean I should change my diet or exercise habits?
This research reinforces why lifestyle changes matter: it shows how fat damages liver cells and triggers the scarring process. Continue following proven strategies—weight loss, reduced sugar, regular exercise—which address the root cause of fatty liver disease.
Want to Apply This Research?
- Users with fatty liver disease could track liver health markers: weight (weekly), waist circumference (monthly), and liver enzyme levels from blood tests (as recommended by their doctor). They could also log dietary changes (sugar intake reduction, processed food elimination) and exercise minutes to correlate with any improvements in liver function tests.
- Based on this research showing how fat damages liver cells and triggers scarring, users could set specific goals: reduce added sugar intake by 50%, increase physical activity to 150 minutes weekly, and achieve a 5-10% weight loss. The app could provide reminders that these changes reduce the fat-induced stress on liver cells that activates the NAT10-TGFβ1 pathway.
- Long-term tracking should include: monthly weight and waist circumference measurements, quarterly liver function tests (ALT, AST) ordered by their doctor, annual ultrasound or elastography to assess liver fibrosis if recommended by their healthcare provider, and continuous logging of diet quality and exercise. Users should share results with their doctor to adjust the plan if liver markers aren’t improving.
This article describes early-stage laboratory and animal research. The findings have not been tested in humans and should not be interpreted as medical advice or a treatment recommendation. NAT10 inhibitors do not currently exist as approved medications. People with fatty liver disease should continue following evidence-based approaches (weight loss, dietary changes, exercise) and work with their healthcare provider. Do not make changes to your treatment plan based solely on this research. Always consult with a qualified healthcare professional, particularly a hepatologist or gastroenterologist, before making decisions about liver disease management.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
